Ann: OLE Study update reveals impressive Survival Data, page-137

I totally agree. MPL has not failed us yet. It just keeps getting better.

Anti-cancer effects displayed in canines - tick

Proven safe in humans - big tick

Signs of efficacy in Phase 1 MEND study - even bigger tick

Yes the concern some might have is the small sample size for phase 1. I would be nervous if the trial showed signs of efficacy in only a minority of patients or the survival data could be attributed to coincidence. But seeing as the data has been “remarkable” in this small cohort, if it can be replicated in the larger phase 2 or even show survival timelines half as good as phase 1, it will still be the leading candidate for MND treatments.

As TheBrownHornet said, nothing is guaranteed, however I personally can’t see any downside to MPL and share the confidence that our board and management have (including our previous board as well, even if they did have their faults in terms of communication and vision).